Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors

Bioorg Med Chem Lett. 2021 Apr 15:38:127862. doi: 10.1016/j.bmcl.2021.127862. Epub 2021 Feb 18.

Abstract

Autoimmune and inflammatory diseases place a huge burden on the healthcare system. Small molecule (SM) therapeutics provide much needed complementary treatment options for these diseases. This digest series highlights the latest progress in the discovery and development of safe and efficacious SMs to treat autoimmune and inflammatory diseases with each part representing a class of SMs, namely: 1) protein kinases; 2) nucleic acid-sensing pathways; and 3) soluble ligands and receptors on cell surfaces. In this first part of the series, the focus is on kinase inhibitors that emerged between 2018 and 2020, and which exhibit increased target and tissue selectivity with the aim of increasing their therapeutic index.

Keywords: Autoimmune and inflammatory diseases; Kinase inhibitors; Kinase selectivity; Small molecule; Therapeutic index.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / metabolism
  • Dose-Response Relationship, Drug
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Molecular Structure
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinases / metabolism*
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Structure-Activity Relationship

Substances

  • Protein Kinase Inhibitors
  • Small Molecule Libraries
  • Protein Kinases